Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 273 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Varenicline tartrate Clear all
Withdrawn Phase 2 Interventional

Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans

NCT05294263
View directory record Official record
Conditions
Tobacco Use Disorder, Cannabis Use Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tobacco Cessation in Public Housing

NCT04889638
View directory record Official record
Conditions
Smoking Cessation, Smoking Reduction, Smoking, Tobacco
Interventions
Cessation Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 11, 2026, 4:50 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Photorefractive Keratectomy (PRK)

NCT05045508
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) nasal spray, Placebo (vehicle) Nasal Spray
Drug
Lead sponsor
Brandon Baartman
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Smoking Among Individuals With PTSD

NCT00937235
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence, Post-traumatic Stress Disorder, Tobacco Use Disorder
Interventions
Varenicline, Medication Management Counseling, Prolonged Exposure
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

PRecision Interventions for SMoking in the SCCS

NCT03521141
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, Varenicline, Nicotine metabolism, Genetically-informed lung cancer risk score, NCI "Clearing the Air"
Drug · Genetic · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Understanding Disparities in Quitting in African American and White Smokers

NCT01836276
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline
Drug
Lead sponsor
Nikki Nollen, PhD, MA
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs

NCT03691350
View directory record Official record
Conditions
Cigarette Smoker, Current Every Day Smoker
Interventions
Bronchoscopy with Bronchoalveolar Lavage, Cigarette, Electronic Cigarette, Laboratory Biomarker Analysis, Nicotine Replacement, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 52 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers

NCT01553084
View directory record Official record
Conditions
Smoking Cessation, Smoking, Nicotine Dependence
Interventions
Varenicline, Nicotine lozenge, Nicotine Patch
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
1,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 3 Interventional

A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation

NCT00143286
View directory record Official record
Conditions
Smoking Cessation
Interventions
varenicline (CP-526,555)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Santa Ana, California • West Palm Beach, Florida • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2007 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Tobacco Intervention in Buprenorphine Treatment

NCT01350011
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Innovative System, Standard Treatment Control (STC)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation

NCT03688802
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-01 (varenicline) nasal spray, Placebo (vehicle control) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 11, 2026, 4:50 PM EDT
Terminated Early Phase 1 Interventional

Smoking Cessation Treatment for Head and Neck Cancer Patients

NCT00931021
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline (Chantix), Nicotine Patch
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Oct 11, 2026, 4:50 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement

NCT01143857
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Varenicline
Drug
Lead sponsor
Jennifer Plebani
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2013 · Synced Oct 11, 2026, 4:50 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Endothelial Function and Autonomic Regulation After Short-term Smoking Cessation: Varenicline Versus Placebo

NCT00673595
View directory record Official record
Conditions
Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

NCT00621777
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 11, 2026, 4:50 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients

NCT02147132
View directory record Official record
Conditions
Cigarette Smoking, Methadone Maintenance
Interventions
Nicotine Nasal Spray, Varenicline, Placebo Nasal Spray, Placebo Varenicline
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 11, 2026, 4:50 PM EDT
Terminated Early Phase 1 Interventional

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT02582008
View directory record Official record
Conditions
Current Smoker, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions
Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement, Quality-of-Life Assessment, Questionnaire Administration, Varenicline
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers

NCT01714323
View directory record Official record
Conditions
Cigarette Smoking, Tobacco Smoking, Tobacco Use Disorder
Interventions
Sustained Care, Standard Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Salem, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

NCT03920215
View directory record Official record
Conditions
Long Term Follow up Dry Eye Disease
Interventions
OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Tobacco Cessation Treatment Preferences Among Veteran Smokers

NCT05277207
View directory record Official record
Conditions
Tobacco Use
Interventions
Personalized Smoking Cessation Facilitation Meetings, Personalized Smoking Cessation Pharmacotherapy, Personalized Text Messaging Support, SmokefreeVET, VA Quitline, Education about pharmacotherapy
Behavioral · Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 11, 2026, 4:50 PM EDT
Not yet recruiting Not applicable Interventional

Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness

NCT07714200
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Cognitive Behavioral Therapy for Smoking Cessation, Nicotine Replacement Therapy, Bupropion, Varenicline, Mobile Contingency Management, Clinic-Based Smoking Cessation Counseling
Behavioral · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

OC-01 (Varenicline) Nasal Spray and Dry Eye Signs and Symptoms in Daily Disposable Contact Lens Wearers

NCT05161208
View directory record Official record
Conditions
Dry Eye
Interventions
OC-01 (varenicline 0.6mg/ml) Nasal Spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Health Systems Reach Interventions Project

NCT04199117
View directory record Official record
Conditions
Smoking, Cigarette, Smoking Cessation
Interventions
Varenicline, Combination nicotine patch and nicotine mini-lozenge treatment, Monetary incentives for initiating treatment, Automated tailored outreach, Care management, Wisconsin Tobacco Quit Line referral, Primary care provider referral, Untailored outreach, Multiple smoking cessation coaching calls
Drug · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 11, 2026, 4:50 PM EDT
Recruiting Phase 3 Interventional

V+PSF-M for Tobacco Cessation in HIV Care in India

NCT05786547
View directory record Official record
Conditions
Human Immunodeficiency Virus, Smoking Cessation, Smoking, Tobacco
Interventions
Varenicline, Positively Smoke Free Mobile (PSF-M), Standard Care
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 11, 2026, 4:50 PM EDT